Loading…
Employees: 102
Size Verastem (VSTM) is a United States Health Care company (Biotechnology) with a market value of $1.02B, the 2232nd largest of 3,117 United States companies the cockpit tracks. Shares closed at $8.41 on 6 Nov 2026.
Performance Over six months the shares gained 72.0%, against -14.0% for the median peer and -1.1% for the United States market (cap-weighted) — highest of 20 in its peer set.
Growth Revenue grew 3,995.7% over the last twelve months (peer median +1.4%); the operating margin is -182.6% (peer median -28.8%).
Valuation It trades at 11.1× enterprise value to sales against a peer median of 5.7× (7th most expensive of 18).
Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $87.5M | $30.9M | $10.0M | $0 | $0 |
| Revenue growth | — | +209% | — | — | — |
| Gross profit | $75.6M | $25.6M | $9.97M | -$62,000 | -$118,000 |
| EBITDA | -$159M | -$169M | -$115M | -$92.0M | -$75.4M |
| Net income | -$203M | -$209M | -$131M | -$87.4M | -$73.8M |
| Free cash flow | -$162M | -$138M | -$105M | -$86.5M | -$63.7M |
| Capital expenditure | $9.62M | $9.62M | $28,000 | $0 | $0 |
| Total debt | $84.3M | $87.2M | $42.3M | $41.6M | $27.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | VSTM | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.7% | -5.6% | 6th highest of 21 |
| 6-month return | +72.0% | -14.0% | highest of 20 |
| Distance from 52-week high | -22.3% | -43.9% | highest of 21 |
| Revenue growth (TTM) | +3,995.7% | +1.4% | 2nd highest of 16 |
| Operating margin | -182.6% | -28.8% | 6th lowest of 18 |
| EV / Sales | 11.1× | 5.7× | 7th most expensive of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Verastem VSTM | United States | $1.02B | +72% | +3,996% | -183% | 11.1× | n/a | n/a |
| Innovita Biological Technology 688253.SS | China | $1.02B | -4% | -28% | 11% | 16.3× | 42.9% | -16.6% |
| Changchun BCHT Biotechnology 688276.SS | China | $1.00B | -11% | +2% | -29% | 10.0× | n/a | n/a |
| Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZ | China | $995M | -11% | 0% | 22% | 4.7× | 11.1% | +2.3% |
| Alto Neuroscience ANRO | United States | $987M | +4% | n/a | n/a | n/a | n/a | n/a |
| Janux Therapeutics JANX | United States | $1.08B | +24% | +5,367% | -598% | 5.3× | n/a | n/a |
| China Animal Husbandry Industry 600195.SS | China | $960M | -17% | +1% | 2% | 1.4× | 6.6% | +4.4% |
| Jade Biosciences JBIO | United States | $958M | -42% | n/a | n/a | n/a | n/a | n/a |
| Daan Gene 002030.SZ | China | $1.11B | -9% | +1% | -81% | 8.4× | 5.7% | -32.3% |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $927M | -54% | n/a | -108% | 26.5× | n/a | n/a |
| Odyssey Therapeutics ODTX | United States | $924M | n/a | -33% | -5,415% | 208.9× | n/a | n/a |
| Guangzhou Wondfo Biotech 300482.SZ | China | $1.14B | -10% | -24% | -2% | 3.2× | 16.4% | -5.8% |
| Inventiva IVA.PA | France | $912M | -29% | -100% | -307,063% | 14,560.9× | n/a | n/a |
| Monte Rosa Therapeutics GLUE | United States | $902M | -45% | -84% | -633% | 11.1× | n/a | n/a |
| Oxford BioMedica OXB.L | United Kingdom | $892M | -14% | +16% | -18% | 4.3× | n/a | n/a |
| Rapport Therapeutics RAPP | United States | $1.17B | -36% | n/a | -838% | 39.3× | n/a | n/a |
| GNI 2160.T | Japan | $866M | -29% | +10% | -24% | 5.7× | n/a | n/a |
| MeiraGTx MGTX | United States | $864M | -8% | +948% | 46% | 2.1× | -9.9% | +39.2% |
| UroGen Pharma URGN | United States | $1.21B | -16% | +159% | -12% | 5.2× | n/a | n/a |
| Syndax Pharmaceuticals SNDX | United States | $859M | -56% | +160% | -62% | 3.5× | n/a | n/a |
| COMPASS Pathways Plc Sponsored ADR CMPS | United States | $1.22B | -13% | n/a | n/a | n/a | n/a | n/a |